FDAnews
www.fdanews.com/articles/204070-moderna-set-to-evaluate-mrna-vaccines-for-hiv

Moderna Set to Evaluate mRNA Vaccines for HIV

August 23, 2021

Moderna is launching a safety, tolerability and immunogenicity study of two messenger RNA (mRNA) vaccines against the human immunodeficiency virus (HIV).

The study is a significant first step in the development of vaccines against HIV, which is a more complex virus than the SARS-CoV-2 coronavirus that causes COVID-19.

The early-phase study will be conducted in 56 healthy adults who are not infected with the virus, according to documents filed at ClinicalTrials.gov.

Dubbed mRNA-1644 and mRNA-1644v2-Core, the vaccines will test whether a priming dose followed by boosters can induce B-cell responses to the vaccine’s HIV protein strands. The hope is to generate broadly neutralizing antibodies against the virus that attach to its protein spikes before it can infect cells.

View today's stories